Graves Disease Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Graves Disease remains an active clinical development field. Clinical competition is shifting from broad immunosuppression toward pathway-selective control, durable remission and treatment strategies that reduce steroid exposure without trading away safety. The PatSnap evidence set used here contains 316 matched trial records and 97 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| ChiCTR2600128186 | Tocilizumab | Not Applicable; Recruiting | Sponsor not listed | China | TRAb seroconversion rate (Tocilizumab combined with ATD Group: Baseline, 4,8,12,16,20,24,36,48,96 weeks…) | 2028-06-30 |
| ChiCTR2600127755 | Methylprednisolone + Teprotumumab-TRBW | Not Applicable; Not yet recruiting | the First Affiliated Hospital of Sun Yat-Sen University | China | Treatment response rate (at the beginning of week 25) | 2030-04-30 |
| NCT07682896 | GenSci098 | Phase 2; Recruiting | Sponsor not listed | United States, Australia | Type and frequency of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) (Baseline, Day 169); Proportion of participants with normal free triiodothyronine (FT3), free thyroxine (FT4), and thyroid-stimulating hormone (TSH) who discontinued anti-thyroid drugs (ATDs), regardless of concomitant levothyroxine use (Baseline, Day 169) | 2027-12-01 |
| ChiCTR2600127106 | Intervention not normalized | Not Applicable; Not yet recruiting | Shanxi Medical University First Hospital | China | Efficacy of 131I treatment and thyroid function indicators (FT3, FT4, TSH) (6 months after the first 131I treatment) | 2028-05-26 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A Phase 2, Proof-of-Concept, Randomized, Double-Masked, Placebo-Controlled Study to Determine the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease (Phase 2): the indexed record reports -; -; Percentage of Participants Showing a Response in Proptosis Measured Using Hertel Exophthalmometer (≥2 mm Decrease From Baseline) in the Study Eye and Separately in Either Eye Without Increased Proptosis (≥2 mm Increase) in the Other Eye = 6 Participants.
- Selenium supplementation in individuals with newly diagnosed Graves’ hyperthyroidism: a double-blind, multi-centre RCT (Not Applicable): the indexed record reports Non-remission = 53.3 %; Non-remission = 54.6 %.
- IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients (Phase 3): the indexed record reports Proptosis response rate(reduction ≥2 mm, at week 24) = 3.8 %; Proptosis response rate(reduction ≥2 mm, at week 24) = 85.8 %.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Tocilizumab (Approved; IL-6RA), Methylprednisolone (Approved; GR), Teprotumumab-TRBW (Approved; IGF-1R), GenSci098 (Phase 1; TSHR). Company & Deal Intelligence records identify sponsor context for the First Affiliated Hospital of Sun Yat-Sen University, Shanxi Medical University First Hospital. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Standard definitions for steroid-free remission and durable disease control.
- Head-to-head trials against current targeted standards, not placebo alone.
- Biomarker strategies that distinguish mechanistic responders before prolonged treatment.
- Long-term infection, malignancy and immune-reconstitution follow-up.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Graves Disease has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
